This shows you the differences between two versions of the page.
Next revision | Previous revision | ||
home:mp:olmesartan:response [01.03.2012] – external edit 127.0.0.1 | home:mp:olmesartan:response [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Patient response to olmesartan (Benicar) | ====== Patient response to olmesartan (Benicar) | ||
+ | |||
+ | < | ||
+ | |||
Olmesartan (Benicar) has two actions. It palliates symptoms by reducing inflammation, | Olmesartan (Benicar) has two actions. It palliates symptoms by reducing inflammation, | ||
Line 16: | Line 19: | ||
Once the body's mechanisms for regulating hormones has adjusted to regular doses of olmesartan, patients may find that they experience immunopathology or an increase in symptoms of disease. It is often the case that this is due to olmesartan' | Once the body's mechanisms for regulating hormones has adjusted to regular doses of olmesartan, patients may find that they experience immunopathology or an increase in symptoms of disease. It is often the case that this is due to olmesartan' | ||
- | Though the immunopathological reaction to olmesartan is near universal in the MP cohort, nothing that would suggest an increase in symptoms is listed in the [[http://medicaidprovider.hhs.mt.gov/pdf/benicar.pdf|monograph for olmesartan]]. In fact, the only adverse event in which olmesartan had a higher incidence than a placebo is for dizziness (3% vs. 1%). However, it should be noted, the patients in these studies were given Benicar only once a day. | + | Though the immunopathological reaction to olmesartan is near universal in the MP cohort, nothing that would suggest an increase in symptoms is listed in the [[https://www.accessdata.fda.gov/drugsatfda_docs/label/ |
This discrepancy underscores how crucial regular dosing of olmesartan is for achieving an immune response. | This discrepancy underscores how crucial regular dosing of olmesartan is for achieving an immune response. | ||
Line 30: | Line 33: | ||
< | < | ||
- | Olmesartan is classified as an Angiotensin II Receptor Blocking (ARB) drug. When olmesartan binds and blocks the Angiotensin Receptor, it prevents fibrotic tissue from forming and [[http:// | + | Olmesartan is classified as an Angiotensin II Receptor Blocking (ARB) drug. When olmesartan binds and blocks the Angiotensin Receptor, it prevents fibrotic tissue from forming and [[https:// |
For this reason, [[dosing|higher doses or more frequent administration]] of olmesartan is strongly recommended during [[home: | For this reason, [[dosing|higher doses or more frequent administration]] of olmesartan is strongly recommended during [[home: | ||
- | {{tag> | + | {{tag>MP olmesartan}} |
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
* Legacy content | * Legacy content | ||
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
===== References ===== | ===== References ===== | ||
- | + | </ |